Key result
Higher CHA2DS2-VA score is linked to ~30% higher no-reflow risk in STEMI, driven entirely by females.
Why the study?
The study evaluated the CHA2DS2-VA score (CV score) as a predictor of the no-reflow phenomenon in STEMI patients undergoing primary PCI.
Does the CHA2DS2-VA score predict the no-reflow phenomenon in STEMI patients undergoing primary PCI?
Observational (n=725)
Single-blind (cardiologists blinded to CV scores and clinical data)
No
Does the CHA2DS2-VA score predict the no-reflow phenomenon in STEMI patients undergoing primary PCI?
The CHA2DS2-VA score is a sex-specific predictor of the no-reflow phenomenon in STEMI patients undergoing primary PCI, demonstrating predictive value in females but not in males.
Answers are grounded in this paper and cite their sources.
May support sex-specific no-reflow risk assessment in STEMI; hypothesis-generating pending prospective validation before clinical use.
METHODS: A total of 725 STEMI patients were retrospectively enrolled and stratified by median of CV score (≤ 2 vs. > 2). The predictive ability of the CV score for NRP was assessed using logistic regression, receiver operating characteristic analysis, and DeLong tests. RESULTS: NRP incidence was higher in the high CV score group (15.2% vs. 8.7%, p = 0.007). The CV score predicted NRP overall (adjusted OR: 1.295, p = 0.002), but this effect was confined to females (AOR: 1.597, p = 0.002), with no significant association in males. Area under the curve value (AUC) of the CV score for predicting NRP was 0.613 in all patients (38.8% sensitivity and 79.1% specificity, p = 0.001) and 0.673 in females (78.1% sensitivity and 47.6% specificity, p = 0.002). A significant sex × CV score interaction (p = 0.017) confirmed sex-modified predictive value. DeLong tests combining the CV score with laboratory markers improved prediction in males but not females. CONCLUSION: The CV score is a sex-specific predictor of NRP in STEMI, with predictive value in females but not males. These findings support a tailored risk stratification approach: using the CV score alone for female patients, while integrating laboratory and procedural markers for male patients.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) conducted an observational in ST-elevation myocardial infarction (STEMI) (n=725). CHA2DS2-VA score vs. Low CHA2DS2-VA score (≤ 2) was evaluated on No-reflow phenomenon (NRP) (OR 1.295, 95% CI 1.098-1.527, p=0.002). The CHA2DS2-VA score independently predicted the no-reflow phenomenon in STEMI patients overall, but this predictive value was entirely confined to female patients with no significant association in males.
Synapse has enriched 10 related papers. Consider them for comparative context: